About hepatitis
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.
Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Vertex Pharmaceuticals
Other prominent vendors
• Abbvie
• Achillion Pharmaceuticals
• Bristol-Myers Squibb
• Dynavax Technologies
• Mitsubishi Tanabe Pharma
Key market driver
• Emergence of IFN-free therapies
• For a full, detailed list, view our report
Key market challenge
• Side-effects of current therapy
• For a full, detailed list, view our report
Key market trend
• Collaborations and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Product offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Understanding the disease
- Classification
- Mode of transmission
- Epidemiology
- Diagnosis
- Symptoms
- Treatment
PART 06: Key marketed drugs
- Hepatitis A
- Hepatitis B
- Hepatitis C
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by type
- Hepatitis A
- Hepatitis B
- Hepatitis C
PART 09: Market segmentation by MOA
- Virus-specific agents
- Non-specific agents
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
- Competitive scenario
- Gilead Sciences
- Johnson & Johnson
- F. Hoffman-La Roche
- Merck
- GlaxoSmithKline
- Vertex Pharmaceuticals
- Novartis
- Other prominent vendors
PART 17: Key vendor analysis
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Roche
- Vertex Pharmaceuticals
PART 18: Appendix
PART 19: Explore Technavio